Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis

Hepatology Research

Volumn 45, Issue 11, 2015, Pages 1083-1090

  Hanai, Tatsunori ^a   Shiraki, Makoto ^a   Ohnishi, Sachiyo ^a   Miyazaki, Tsuneyuki ^a   Ideta, Takayasu ^a   Kochi, Takahiro ^a   Imai, Kenji ^a   Suetsugu, Atsushi ^a   Takai, Koji ^a   Shimizu, Masahito ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Liver cirrhosis; Liver fibrosis; Liver function reserves; Survival; Wisteria floribunda agglutinin positive Mac 2 binding protein

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BINDING PROTEIN; GELATINASE A; HYALURONIC ACID; UNCLASSIFIED DRUG; WISTERIA FLORIBUNDA AGGLUTININ POSITIVE MAC 2 BINDING PROTEIN;

ADULT; AGED; ARTICLE; CHILD PUGH SCORE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE;

EID: 84947506456     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12473     Document Type: Article

References (32)

1. Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol 2011; 26: 802-9.
2. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134: 1670-81.
3. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006; 43: S113-20.
4. Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 1993; 38: 1480-4.
5. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68, 276 biopsies. J Hepatol 1986; 2: 165-73.
6. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
7. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
8. Maharaj B, Maharaj RJ, Leary WP et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-25.
9. McGary CT, Raja RH, Weigel PH. Endocytosis of hyaluronic acid by rat liver endothelial cells. Evidence for receptor recycling. Biochem J 1989; 257: 875-84.
10. Oberti F, Valsesia E, Pilette C et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113: 1609-16.
11. Yamada S, Suou T, Kawasaki H, Yoshikawa N. Clinical significance of serum 7S collagen in various liver diseases. Clin Biochem 1992; 25: 467-70.
12. Suou T, Yamada S, Hosho K, Yoshikawa N, Kawasaki H. Relationship between serum and hepatic 7S fragments of type IV collagen in chronic liver disease. Hepatology 1996; 23: 1154-8.
13. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
14. Lackner C, Struber G, Liegl B et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376-82.
15. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912-21.
16. Vallet-Pichard A, Mallet V, Nalpas B et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.
17. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
18. Shah AG, Lydecker A, Murray K et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-12.
19. Yu ML, Lin SM, Lee CM et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 2006; 44: 1086-97.
20. Martinez SM, Fernandez-Varo G, Gonzalez P et al. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 138-48.
21. Nunes D, Fleming C, Offner G et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105: 1346-53.
22. Kuno A, Ikehara Y, Tanaka Y et al. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013; 3: 1065.
23. Artini M, Natoli C, Tinari N et al. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996; 25: 212-7.
24. Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J 1998; 17: 1606-13.
25. Yamasaki K, Tateyama M, Abiru S et al. Elevated serum levels of WFA -M2BP predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology, 2014. doi: 10.1002/hep.27305.
26. Toshima T, Shirabe K, Ikegami T et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP), for assessing liver fibrosis. J Gastroenterol 2014. doi: 10.1007/s00535-014-0946-y.
27. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
28. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
29. Nord HJ. Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques--a review. Gastrointest Endosc 1982; 28: 102-4.
30. Kim HY, Choi JY, Park CH et al. Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis. J Gastroenterol 2013; 48: 1180-7.
31. Muto Y, Sato S, Watanabe A et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 705-713.
32. Elkrief L, Chouinard P, Bendersky N et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology 2014; 60: 823-831.